Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1980 1
1986 1
1987 1
1988 2
1990 1
2007 1
2008 2
2012 2
2013 2
2014 2
2015 3
2016 5
2017 4
2018 5
2019 4
2020 5
2021 10
2022 13
2023 13
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Advanced and recurrent endometrial cancer: State of the art and future perspectives.
Tronconi F, Nero C, Giudice E, Salutari V, Musacchio L, Ricci C, Carbone MV, Ghizzoni V, Perri MT, Camarda F, Gentile M, Berardi R, Scambia G, Lorusso D. Tronconi F, et al. Among authors: nero c. Crit Rev Oncol Hematol. 2022 Dec;180:103851. doi: 10.1016/j.critrevonc.2022.103851. Epub 2022 Oct 17. Crit Rev Oncol Hematol. 2022. PMID: 36257537 Review.
Verification of the prognostic precision of the new 2023 FIGO staging system in endometrial cancer patients - An international pooled analysis of three ESGO accredited centres.
Schwameis R, Fanfani F, Ebner C, Zimmermann N, Peters I, Nero C, Marth C, Ristl R, Leitner K, Grimm C, Oberndorfer F, Capasso I, Zeimet AG, Polterauer S, Scambia G, Fagotti A, Concin N. Schwameis R, et al. Among authors: nero c. Eur J Cancer. 2023 Nov;193:113317. doi: 10.1016/j.ejca.2023.113317. Epub 2023 Sep 1. Eur J Cancer. 2023. PMID: 37748967 Free article.
PTEN and Gynecological Cancers.
Nero C, Ciccarone F, Pietragalla A, Scambia G. Nero C, et al. Cancers (Basel). 2019 Sep 28;11(10):1458. doi: 10.3390/cancers11101458. Cancers (Basel). 2019. PMID: 31569439 Free PMC article. Review.
Immunotherapy in gynecological cancers.
Lorusso D, Ceni V, Daniele G, Pietragalla A, Salutari V, Muratore M, Nero C, Ciccarone F, Scambia G. Lorusso D, et al. Among authors: nero c. Explor Target Antitumor Ther. 2021;2(1):48-64. doi: 10.37349/etat.2021.00033. Epub 2021 Feb 28. Explor Target Antitumor Ther. 2021. PMID: 36046088 Free PMC article. Review.
PARP Inhibitors Resistance: Mechanisms and Perspectives.
Giudice E, Gentile M, Salutari V, Ricci C, Musacchio L, Carbone MV, Ghizzoni V, Camarda F, Tronconi F, Nero C, Ciccarone F, Scambia G, Lorusso D. Giudice E, et al. Among authors: nero c. Cancers (Basel). 2022 Mar 10;14(6):1420. doi: 10.3390/cancers14061420. Cancers (Basel). 2022. PMID: 35326571 Free PMC article. Review.
Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Cesari E, Ciucci A, Pieraccioli M, Caggiano C, Nero C, Bonvissuto D, Sillano F, Buttarelli M, Piermattei A, Loverro M, Camarda F, Greco V, De Bonis M, Minucci A, Gallo D, Urbani A, Vizzielli G, Scambia G, Sette C. Cesari E, et al. Among authors: nero c. J Exp Clin Cancer Res. 2023 May 18;42(1):126. doi: 10.1186/s13046-023-02682-5. J Exp Clin Cancer Res. 2023. PMID: 37202753 Free PMC article.
Integration of PARP-inhibitors in ovarian cancer therapy.
Pietragalla A, Ciccarone F, Nero C, Scambia G, Lorusso D, Daniele G. Pietragalla A, et al. Among authors: nero c. Explor Target Antitumor Ther. 2020;1(3):171-182. doi: 10.37349/etat.2020.00011. Epub 2020 Jun 29. Explor Target Antitumor Ther. 2020. PMID: 36046198 Free PMC article. Review.
Management of stage III and IVa uterine cancer.
Nero C, Tronconi F, Giudice E, Scambia G, Lorusso D. Nero C, et al. Int J Gynecol Cancer. 2022 Mar;32(3):316-322. doi: 10.1136/ijgc-2021-002554. Int J Gynecol Cancer. 2022. PMID: 35256418 Review.
78 results